Clinical Post-Transplant Lymphoproliferative Disorders

Ziba Aghsaeifard; Reza Alizadeh

doi:10.2174/1871529X22666220804155810

Clinical Post-Transplant Lymphoproliferative Disorders

Cardiovasc Hematol Disord Drug Targets. 2022;22(2):96-103. doi: 10.2174/1871529X22666220804155810.

Authors

Ziba Aghsaeifard¹, Reza Alizadeh²

Affiliations

¹ Department of Internal Medicine, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
² Department of Anesthesiology and Intensive Care, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.

PMID: 35927798
DOI: 10.2174/1871529X22666220804155810

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are characterized by hyperproliferation of B cells due to solid organ or allogeneic hematopoietic stem cell transplant. Based on histological findings, it is divided into 4 categories. Most PTLD patients are Epstein-Barr virus (EBV) positive. Additionally, aggressive immunosuppressive therapies can also lead to PTLD. Reducing immunosuppressive regimes, antivirals, monoclonal antibodies, chemotherapy, and radiotherapy are available therapeutic options, depending on the nature and phase of the disease. This review briefly highlights pathogenesis, risk factors, prevention, and therapeutic strategies regarding PTLDs.

Keywords: Epstein-Barr virus (EBV); hematopoietic stem cell; immunosuppression; lymphoma; post-transplant lymphoproliferative disorders (PTLD); transplant recipients.

Publication types

Review

MeSH terms

Epstein-Barr Virus Infections* / complications
Epstein-Barr Virus Infections* / drug therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Herpesvirus 4, Human
Humans
Lymphoproliferative Disorders* / etiology
Lymphoproliferative Disorders* / therapy
Risk Factors